Senexis and Biofocus collaborate to select development candidates for Senexis' Alzheimer's Disease targets

06-Dec-2005

Senexis Limited, a private drug development company, and Galapagos NV announced that they have expanded their collaboration to optimise Senexis' novel inhibitors of amyloid-induced toxicity and neuroinflammation for the treatment of Alzheimer's disease. Galapagos will receive research fees for the medicinal chemistry services provided to Senexis. The collaboration aims to significantly advance Senexis' small molecule Alzheimer's programs towards the clinic and is unrelated to Galapagos' own Alzheimer's disease targets program.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents